



Clinical Updates in Breast Cancer From San Antonio

Clinical Update 1 – Datopotamab Deruxtecan for HR+/HER2– Breast Cancer: Results From the Phase 3 TROPION-Breast01 Trial

References

Tweet 2 References:

AstraZeneca. Datopotamab deruxtecan demonstrated statistically significant and clinically meaningful progression-free survival benefit in patients with HR-positive, HER2-low or negative breast cancer in TROPION-Breast01 Phase III trial. Updated September 22. Accessed September 28, 2023.

<https://www.astrazeneca.com/media-centre/press-releases/2023/dato-dxd-improved-pfs-in-breast-cancer.html>

Bardia A, Jhaveri K, Im S-A, et al. (GS02-01) Randomized phase 3 study of datopotamab deruxtecan vs chemotherapy for patients with previously-treated inoperable or metastatic hormone receptor-positive, HER2-negative breast cancer: Results from TROPION-Breast01. Presented at: SABCS; December 5–9 2023; San Antonio, TX. Accessed December 6, 2023.

<https://sabcs2023.eventscribe.net/fsPopup.asp?PresentationID=1329791&query=tropion%2Dbreast01&Mode=presInfo>

Meric-Bernstam F, Krop I, Juric D, et al. PD13-08 Phase 1 TROPION-PanTumor01 study evaluating datopotamab deruxtecan (Dato-DXd) in unresectable or metastatic hormone receptor-positive/HER2-negative breast cancer (BC). *Cancer Res.* 2023;83(5_Supplement):PD13-08. doi:10.1158/1538-7445.Sabcs22-pd13-08

Additional References:

Bardia A, Jhaveri K, Im SA, et al. LBA11 Datopotamab deruxtecan (Dato-DXd) vs chemotherapy in previously-treated inoperable or metastatic hormone receptor-positive, HER2-negative (HR+/HER2–) breast cancer (BC): Primary results from the randomised phase III TROPION-Breast01 trial. *Ann Oncol.* 2023;34:S1264-S1265. doi:10.1016/j.annonc.2023.10.015

National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): Breast Cancer (v5.2023). Updated December 5, 2023. Accessed December 7, 2023.

https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf



2L, second line
3L, third line
ADC, antibody-drug conjugate
BC, breast cancer
CDK, cyclin-dependent kinase
CI, confidence interval
Dato-DXd, datopotamab deruxtecan
DCR, disease control rate
ET, endocrine therapy
HER2-, human epidermal growth factor receptor 2
HR, hazard ratio
HR+, hormone receptor positive
i, inhibitor
ICC, investigator's choice of chemotherapy
IHC, immunohistochemistry
MBC, metastatic breast cancer
Mets, metastases
ORR, objective response rate
OS, overall survival
P1, phase 1
P3, phase 3
PFS, progression-free survival
TRAE, treatment-related adverse event
TROP2, trophoblast cell-surface antigen 2
TTD, time to deterioration
TTFST, time to first subsequent treatment
w/, with
yo, year old